checkAd
    Startseite > Aktien > NextCure > Nachrichten
    NextCure Aktie
    1,1440
     
    EUR
    +1,60 %
    +0,0180 EUR
    Letzter Kurs 10:09:40 Tradegate
    1,1240
     
    EUR
    2.696 STK
    Geldkurs 13:02:09
    1,1560
     
    EUR
    2.617 STK
    Briefkurs 13:02:09
    ISIN: US65343E1082 · WKN: A2PHHE · SYM: 2US · USA

    Neueste Nachrichten

    NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
    30.05.24 · globenewswire · NextCure
    NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
    02.05.24 · globenewswire · NextCure
    NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
    24.04.24 · globenewswire · NextCure
    NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
    08.04.24 · globenewswire · NextCure
    NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
    04.04.24 · globenewswire · NextCure
    NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
    02.04.24 · globenewswire · NextCure
    NextCure Provides Business Update and Reports Full Year 2023 Financial Results
    21.03.24 · globenewswire · NextCure
    NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
    05.03.24 · globenewswire · NextCure
    NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
    18.01.24 · globenewswire · NextCure
    NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
    21.12.23 · globenewswire · NextCure
    NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
    20.11.23 · globenewswire · NextCure
    NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
    15.11.23 · globenewswire · NextCure